DOCSLIB.ORG

Mns Meeting 2015 Santa Margherita Di Pula, 12-‐15

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mns Meeting 2015 Santa Margherita Di Pula, 12-‐15 PROGRAM MNS MEETING 2015 SANTA MARGHERITA DI PULA, 12-15 JUNE 2015 Santa Margherita di Pula, 12-15 June 2015 ORGANIZED UNDER THE AUSPICES OF Università degli Studi di Cagliari Santa Margherita di Pula, 12-15 June 2015 SPONSORS Santa Margherita di Pula, 12-15 June 2015 EXHIBITORS Santa Margherita di Pula, 12-15 June 2015 LOCAL ORGANIZING COMMITTEE Liana Fattore (Cagliari) Cristina Cadoni (Cagliari) Anna Carta (Cagliari) Marco Diana (Sassari) Miriam Melis (Cagliari) Annalisa Pinna (Cagliari) Valentina Valentini (Cagliari) Patrizia Campolongo (Roma) Carla Cannizzaro (Palermo) Paola Fadda (Cagliari) Patrizia Fattori (Bologna) Walter Fratta (Cagliari) Micaela Morelli (Cagliari) SCIENTIFIC COMMITTEE Marie Moftah President Egypt Marc Landry President Elect France Nora Abrous General Secretary France Hagai Bergman Vice Secretary Israel Abdelhamid Benazzouz Treasurer France Yasin Temel Vice Treasurer Netherlands Hedayat Abdel Ghaffar Council Member Egypt Latifa Dorbani-Mamine Council Member Algeria Mohammed Errami Council Member Morocco Liana Fattore Council Member Italy Patrizia Fattori Council Member Italy Suleyman Kaplan Council Member Turkey Mohammed Najimi Council Member Morocco Maria-Paz Viveros Council Member Spain Secretariat of the 5th MNS Meeting 2015 Monica Valentini PROGRAM 7 Santa Margherita di Pula, 12-15 June 2015 Friday, June 12th 2015 13.00 - 19.00 Registration Room: NAUTILUS 13.45 - 14.00 MNS Presentation & Introduction to the Meeting Marie Moftah, MNS President, Liana Fattore, President of the 2015 MNS Meeting 14.00 - 14.30 Presentation of COST ACTIONS Graziano Fiorito & Laura Della Corte 14.30-15.30 PLENARY LECTURE GAETANO DI CHIARA (Italy): Drugs of abuse as unconditioned homologs of conditioned rewards: the role of accumbens shell dopamine Host: Carla Cannizzaro 15.30 - 17.15 SYMPOSIA Room: NAUTILUS Neurocognitive function and emotion processing in psychopathology Chairs: Adrianna Mendrek (Canada) & Walter Fratta (Italy) FLORINE DOLCOS (USA): “Neural mechanisms of emotion-cognition interactions in healthy functioning and disease: Evidence from brain imaging investigations”. ANDRIANNA MENDREK (Canada): “Functional cerebral connectivity in schizophrenia women during visuo-spatial processing”. ANGELA SIRIGU (France): “How oxytocin modulates the human brain and behavior”. HELENE POISSANT (Canada): “Transmission of fronto-parietal dysfunction during forethought in families with attention deficit/hyperactivity disorder”. 8 Friday, June 12th 2015 Santa Margherita di Pula, 12-15 June 2015 Room CYPREA Emerging concepts in dopaminergic system development and regulation Chairs: Stefano Espinoza (Italy) & Małgorzata Filip (Poland) ELIA DI SCHIAVI (Italy): “Genetic characterization of the dopamine system in the animal model C. elegans” GIUSEPPE RONZITTI (France): “HDAC inhibition reduces dopamine-dependent neurodegeneration in a mouse model of DAT-deficiency syndrome” DAMIANA LEO (Italy): “Pronounced dopaminergic dysregulation in dopamine transporter knock out rats” DAVID MORENO (France): “Targeting dopamine D1-histamine H3 receptor heteromers reverts learning and long-term memory deficits in a mouse model of Huntington’s disease”. MASSIMILIANO CAIAZZO (Italy): “Direct reprogramming of fibroblasts into functional dopaminergic neurons”. Room ASTREA Glia in the nervous system: From housekeeping to processing functions Chairs: Stéphane Oliet (France) & Anna R. Carta (Italy) STEPHANE OLIET (France): “Surface dynamics of GLT-1 on astrocytes shapes excitatory transmission”. STEPHEN D. SKAPER (Italy): “Co-ultramicronized palmitoylethanolamide/luteolin promotes maturation of rat cortical oligodendrocytes in vitro”. NATHALIE ROUACH (France): “Connexin 30: unconventional determinant of astroglial synapse coverage and memory”. ESTEE KURANT (Israel): “Keeping the CNS clear: Glial phagocytosis of neuronal debris”. ARNAU BUSQUETS-GARCIA (France): “Involvement of astrocytic CB1 receptors in synaptic plasticity and hippocampal-based memory”. 9 th Santa Margherita di Pula, 12-15 June 2015 Friday, June 12 2015 Room ALVANIA Neurobiology of food intake regulation Chairs: Carole Rovere (France) & Mohamed Najimi (Morocco) SERGE LUQUET (France): “Dietary triglycerides act on mesolimbic structures to regulate the rewarding and motivational aspects of feeding”. ETIENNE CHALLET (France): “Timed feeding: impact on circadian clocks and metabolism”. MOHAMMED ERRAMI (Morocco): “Molecular mechanisms underlying cannabinoids action on hypothalamic neuropeptide neurons”. CAROLE ROVERE (France): Role of chemokines in neuroinflammation and feeding behavior”. NICOLAS CHARTREL (France): “26RFa, a novel neuropeptide regulating feeding behavior and glucose homeostasis”. 17.15 - 17.45 Coffee break 17.45 - 19.30 SYMPOSIA Room NAUTILUS Depression, anxiety and addiction: is it all converge to impaired dopaminergic function? Chairs: Rami Yaka (Israel) & Barry J. Everitt (UK) CHRISTINA DALLA (Greece) : “Sex differences in models of depression: is it all about serotonin?” MIRIAM MELIS (Italy): “Effects of in utero exposure to cannabinoids on postnatal synaptic maturation of glutamatergic transmission in the VTA “. FRANCOIS GEORGES (France): “In vivo homeostatic plasticity at the single-cell level in the BNST triggers persistent anxiolytic effect”. RAMI YAKA (Israel): “Targeting drug-cue associations to prevent drug relapse”. MARK UNGLESS (UK): “Functional diversity of midbrain dopamine neurons”. 10 th Santa Margherita di Pula, 12-15 June 2015 Friday, June 12 2015 Room CYPREA Parkinson’s disease - from neuroprotection to the treatment of motor and non- motor symptoms Chairs: Gilberto Fisone (Sweden) & Moussa Youdim (Israel) ANNA CARTA (Italy): “Microgliosis in Parkinson’s disease: can we harness it for good?” NEVILLE VASSALLO (Malta): “Amyloid-lipid membrane interaction: a novel target for neurodegeneration“. RICCARDO BRAMBILLA (Italy): “Intracellular signalling mechanisms controlling L-DOPA induced Dyskinesia: a translational neuroscience perspective”. GILBERTO FISONE (Sweden): “Cognitive and affective dysfunctions in experimental Parkinsonism: modeling and mechanisms”. ROSARIO MORATALLA (Spain): “Activation of DREAM, a calcium-binding protein, reduces L- DOPA- induced dyskinesias in mice”. Room ASTREA Neuronal plasticity in health and disease: cognitive and clinical perspectives Chairs: Said Boujraf (Morocco) & Driss Boussaoud (France) JULIEN DOYON (Canada): “Neural and physiological correlates of motor learning and consolidation”. HABIB BENALI (France): “Longitudinal functional network analysis for motor skill learning in humans”. MOHAMMED BENZAGMOUT (Morocco): “Brain plasticity induced by hemodialysis: neuroanatomical and BOLD-fMRI study”. DRISS BOUSSAOUD (France): “Social learning: from behavior to neurons“. YVES JOANETTE (Canada): “Brain, communication and aging: a life-long adaptive process sustaining quality of life”. 11 th Santa Margherita di Pula, 12-15 June 2015 Friday, June 12 2015 Room ALVANIA Genes do matter: insights in the genetic vulnerability to nicotine addiction Chairs: Cristina Cadoni (Italy) & Nataliè Thiriet (France) LAURIANE HARRINGTON (France): “The role of nicotinic acetylcholine receptor subunits in nicotine addiction”. CRISTINA CADONI (Italy): “Strain differences in the long lasting effect of adolescent nicotine exposure on mesolimbic dopamine transmission of Lewis and Fischer 344 rats”. JENNIFER J. WARE (UK): “Using biomarkers of tobacco exposure in genome-wide association studies”. MORGANE BESSON (France): “The rs16969968 polymorphism predisposing to smoking confers midbrain- and hippocampus-dependent affective impairments that are alleviated by nicotine”. 19.30 - 20.30 WELCOME COCKTAIL 12 Santa Margherita di Pula, 12-15 June 2015 Saturday, June 13th 2015 Room NAUTILUS 8.30 - 9.30 PLENARY LECTURE IDAN SEGEV – “The Human Brain Project: from Mouse to Man” Host: Marco Diana 9.30 - 11.15 SYMPOSIA Room NAUTILUS Interaction between dopaminergic and non-dopaminergic neurotransmission on Parkinson’s disease: implication in therapy, dyskinesia and neuroprotection Chairs: Marie-Therese Armentero (Italia) & Rosario Moratalla (Spain) ANNALISA PINNA (Italy): “Novel therapeutic strategy for the control of dyskinesia in the therapy of Parkinson’s disease: acute and chronic studies”. MARIANNE AMALRIC (France): “Bee venom and apamin, a small conductance calcium- activated potassium channel blocker, are potential new therapeutic targets for Parkinson's disease”. RODRIGO A. CUNHA (Portugal): “ATP and adenosine modulation of striatal plasticity and Parkinson's disease”. MARIE-THERESE ARMENTERO (Italy): “Neuroprotective and symptomatic potential of combined non- dopaminergic therapy in Parkinson’s disease”. KRYSTYNA GOLEMBIOWSKA (Poland): “The antioxidative and anti-inflammatory effects of adenosine A2A receptor antagonist as a new therapy of PD”. 13 Saturday, June 13th 2015 Santa Margherita di Pula, 12-15 June 2015 Room CYPREA Serotonin interaction with other neurotransmitters Chairs: Giuseppe Di Giovanni (Malta) & Philippe De Deurwaerdère (France) PHILIPPE DE DEURWAERDERE (France): “A closer look at the pivotal role of serotonergic neurons in the mechanism of action of L-DOPA”. GIUSEPPE DI GIOVANNI (Malta): “5-HT2C receptor control of generalized and focal seizures”. MASSIMO PIERUCCI (Malta): “Role of the lateral habenula in nicotine addiction“. NELA PIVAC (Croatia): “Serotonin and dopamine in sleep disturbances in PTSD”. Room ASTREA The GABA-B receptor: from molecular to behavioral regulation! Chairs: Maria Paola Castelli (Italy) & Bernhard Bettler (Switzerland)
Load more

Recommended publications
  • NMDA Receptor Dynamics Dictate Neuronal Plasticity and Function
    NMDA Receptor Dynamics Dictate Neuronal Plasticity and Function Tommy Weiss Sadan, Ph.D. and Melanie R. Grably, Ph.D. N-Methyl-D-Aspartate Receptor (NMDAR) are ubiquitously expressed along the central nervous system and are instrumental to various physiological processes such as synaptic plasticity and learning. Nevertheless, several mental disabilities including schizophrenia and Alzheimer’s disease are all related to NMDAR dysfunction. Here, we review many aspects of NMDAR function and regulation and describe their involvement in pathophysiological states using Alomone Labs products. Right: Cell surface detection of GluN2B in rat hippocampal neurons. Introduction Mechanism of Action Glutamate is a key neuro-transmitter in the central nervous system and NMDAR activation depends on sequential conformational changes to acts on a variety of cell surface receptors, collectively termed ionotropic relieve the magnesium blockade which is achieved by rapid membrane glutamate receptors (iGluRs)15. The N-Methyl-D-Aspartate receptors (NMDAR) depolarization and binding of both glycine and glutamate ligands6, 21. This in are members of the iGluR superfamily and are pivotal to many physiological turn removes the inhibitory electrostatic forces of magnesium and enables processes such as the formation of long term memory, synaptic plasticity calcium influx and transmission of long lasting signals (i.e. long-term and many other cognitive functions. Therefore, it is not surprising that potentiation), a key mechanism to learning and memory formation10.
    [Show full text]
  • Stimulation Du Cortex Préfrontal: Mécanismes Neurobiologiques De
    Stimulation du cortex préfrontal : Mécanismes neurobiologiques de son effet antidépresseur Adeline Etievant To cite this version: Adeline Etievant. Stimulation du cortex préfrontal : Mécanismes neurobiologiques de son effet an- tidépresseur. Médecine humaine et pathologie. Université Claude Bernard - Lyon I, 2012. Français. NNT : 2012LYO10021. tel-00865594 HAL Id: tel-00865594 https://tel.archives-ouvertes.fr/tel-00865594 Submitted on 24 Sep 2013 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Année 2012 Thèse n°021 - 2012 THESE pour le DOCTORAT DE L’UNIVERSITE CLAUDE BERNARD LYON 1 Ecole doctorale Neurosciences et Cognition Discipline : Neurosciences Soutenue publiquement 23 février 2012 Par Adeline ETIÉVANT STIMULATION DU CORTEX PREFRONTAL : Mécanismes neurobiologiques de son effet antidépresseur Membres du jury : Mr. François JOURDAN Président Mr. Bruno GUIARD Rapporteur Mr. Raymond MONGEAU Rapporteur Mme. Véronique COIZET Examinateur Mr. Bruno MILLET Examinateur M. Nasser HADDJERI Directeur de thèse REMERCIEMENT " " Lg" uqwjckvg" vqwv" f)cdqtf"
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,748,131 B2 Ford (45) Date of Patent: Jun
    USOO8748131B2 (12) United States Patent (10) Patent No.: US 8,748,131 B2 Ford (45) Date of Patent: Jun. 10, 2014 (54) CHIMERIC NEUREGULINS AND METHOD in Neuregulin-1/ErbB Signaling. The Journal of Biological Chemis OF MAKING AND USE THEREOF try vol. 285, No. 41, pp. 31388-31398, Oct. 8, 2010.* Veronese et al., PEGylation. Successful approach to drug delivery. (71) Applicant: Morehouse School of Medicine, Drug Discovery Today vol. 10, No. 21 Nov. 2005, 1451-1458.* Atlanta, GA (US) Carraway et al., Neuregulin-2, a new ligand ErbB3/ErbB4-receptor tyrosine kinases. Nature, vol. 387, May 29, 1997, 512-516.* (72) Inventor: Byron D. Ford, Atlanta, GA (US) Higashiyamaet al., ANovel Brain-Derived Member of the Epidermal Growth Factor Family That Interacts with ErbB3 and ErbB4. J. (73) Assignee: Morehouse School of Medicine, Biochem. 122,675-680 (1997).* Atlanta, GA (US) Fischbach et al., “ARIA: A Neuromuscular Junction Neuregulin.” Annual Review of Neuroscience, 1997, pp. 429–458, vol. 20. (*) Notice: Subject to any disclaimer, the term of this Buonanno et al., “Neuregulin and ErbB receptor signaling pathways patent is extended or adjusted under 35 in the nervous system.” Current Opinion in Neurobiology, 2001, pp. U.S.C. 154(b) by 0 days. 287-296, vol. 11. Burden et al., “Neuregulins and Their Receptors: A Versatile Signal Appl. No.: 13/627,555 ing Module in Organogenesis and Oncogenesis. Neuron, 1997, pp. (21) 847-855, vol. 18. Fu et al., “Cdk5 is involved in neuregulin-induced AChR expression (22) Filed: Sep. 26, 2012 at the neuromuscular junction.” Nature Neuroscience, Apr.
    [Show full text]
  • JPET #82990 Identification of Subunit-Specific and Antagonist
    JPET Fast Forward. Published on March 2, 2005 as DOI: 10.1124/jpet.104.082990 JPET ThisFast article Forward. has not been Published copyedited onand formatted.March 2, The 2005 final versionas DOI:10.1124/jpet.104.082990 may differ from this version. JPET #82990 Identification of subunit-specific and antagonist-specific amino acid residues in the NMDA receptor glutamate binding pocket Downloaded from Leo Kinarsky1, Bihua Feng1, Donald A. Skifter, Richard M. Morley, Simon Sherman, jpet.aspetjournals.org David E. Jane, and Daniel Monaghan. 1The Eppley Research Institute (L.K., S.S.) and the Department of Pharmacology (B.F., D.A.S., D.T.M.) University of Nebraska Medical Center; and Department of Pharmacology, University of Bristol, Bristol, U.K. (R.M.M., at ASPET Journals on September 26, 2021 D.E.J.). 1 Copyright 2005 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on March 2, 2005 as DOI: 10.1124/jpet.104.082990 This article has not been copyedited and formatted. The final version may differ from this version. JPET #82990 Running title: NR2 glutamate binding site models Correspondence: Downloaded from Daniel T. Monaghan, Ph.D. Department of Pharmacology 985800 Nebraska Medical Center jpet.aspetjournals.org Omaha, NE 68198-5800 402-559-7196, FAX: 402-559-7495, e-mail: [email protected] at ASPET Journals on September 26, 2021 Pages: 19 Tables: 0 Figures: 6 References: 40 Number of words Abstract: 243 Introduction: 607 Discussion: 1369 2 JPET Fast Forward. Published on March 2, 2005 as DOI: 10.1124/jpet.104.082990 This article has not been copyedited and formatted.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0178307 A1 Bartlett Et Al
    US 2006O1783 07A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0178307 A1 Bartlett et al. (43) Pub. Date: Aug. 10, 2006 (54) MODULATION OF NMDA RECEPTOR Publication Classification CURRENTS VIA OREXN RECEPTOR AND/OR CRF RECEPTOR (51) Int. Cl. A6II 38/22 (2006.01) (75) Inventors: Selena Bartlett, Berkeley, CA (US); A6II 3L/495 (2006.01) Antonello Bonci, San Francisco, CA A61K 31/4745 (2006.01) (US); Stephanie Borgland, San A61K 31/4706 (2006.01) Francisco, CA (US); Howard Fields, A6II 3/17 (2006.01) Berkeley, CA (US); Sharif Taha, (52) U.S. Cl. ...................... 514/12: 514/255.01: 514/300; Berkeley, CA (US) 514/313; 514/585; 514/595 (57) ABSTRACT Correspondence Address: QUINE INTELLECTUAL PROPERTY LAW This invention pertains to the discoveries that orexin and/or GROUP, PC. CRF increase NMDAR (N-methyl-D-aspartate receptor)- PO BOX 458 mediated currents at excitatory synapses onto a Subset of dopamine cells in the ventral tegmental area (VTA) in the ALAMEDA, CA 94501 (US) mammalian brain. The orexin effect can be blocked by an (73) Assignee: The Regents of the University of Cali orexin receptor type 1 (OXR1). The CRF effect can be blocked by a CRF receptor 2 (CRF-R2) antagonist or by an fornia inhibitor of the CRF-binding protein (CRF-BP). Methods (21) Appl. No.: 11/343,259 are provided that exploit these discoveries to modulate NMDAR-mediated currents in vivo and in vitro and to (22) Filed: Jan. 25, 2006 screen for modulators (upregulators or downregulators) of NMDA-mediated currents. In vivo methods include the use Related U.S.
    [Show full text]
  • A Review of Glutamate Receptors I: Current Understanding of Their Biology
    J Toxicol Pathol 2008; 21: 25–51 Review A Review of Glutamate Receptors I: Current Understanding of Their Biology Colin G. Rousseaux1 1Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada Abstract: Seventy years ago it was discovered that glutamate is abundant in the brain and that it plays a central role in brain metabolism. However, it took the scientific community a long time to realize that glutamate also acts as a neurotransmitter. Glutamate is an amino acid and brain tissue contains as much as 5 – 15 mM glutamate per kg depending on the region, which is more than of any other amino acid. The main motivation for the ongoing research on glutamate is due to the role of glutamate in the signal transduction in the nervous systems of apparently all complex living organisms, including man. Glutamate is considered to be the major mediator of excitatory signals in the mammalian central nervous system and is involved in most aspects of normal brain function including cognition, memory and learning. In this review, the basic biology of the excitatory amino acids glutamate, glutamate receptors, GABA, and glycine will first be explored. In the second part of this review, the known pathophysiology and pathology will be described. (J Toxicol Pathol 2008; 21: 25–51) Key words: glutamate, glycine, GABA, glutamate receptors, ionotropic, metabotropic, NMDA, AMPA, review Introduction and Overview glycine), peptides (vasopressin, somatostatin, neurotensin, etc.), and monoamines (norepinephrine, dopamine and In the first decades of the 20th century, research into the serotonin) plus acetylcholine. chemical mediation of the “autonomous” (autonomic) Glutamatergic synaptic transmission in the mammalian nervous system (ANS) was an area that received much central nervous system (CNS) was slowly established over a research activity.
    [Show full text]
  • WO 2009/106516 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 3 September 2009 (03.09.2009) WO 2009/106516 Al (51) International Patent Classification: BRONZOVA, Juliana B. [BG/NL]; c/o SOLVAY A61K 31/496 (2006.01) A61P 25/14 (2006.01) PHARMACEUTICALS B.V., IPSI DEPARTMENT, CJ. A61P 25/16 (2006.01) A61P 25/00 (2006.01) VAN HOUTENLAAN 36, NL-1381 CP WEESP (NL). (21) International Application Number: (74) Agent: VERHAGE, Marinus; OCTROOIBUREAU PCT/EP2009/052148 ZOAN B.V., P.O. BOX 140, NL-1380 AC WEESP (NL). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 24 February 2009 (24.02.2009) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (25) Filing Language: English CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, (26) Publication Language: English EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/03 1,1 34 25 February 2008 (25.02.2008) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, 0815 1861 .5 25 February 2008 (25.02.2008) EP NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, 08160104.9 10 July 2008 (10.07.2008) EP SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, 61/079,558 10 July 2008 (10.07.2008) US UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • SZDB: a Database for Schizophrenia Genetic Research
    Schizophrenia Bulletin vol. 43 no. 2 pp. 459–471, 2017 doi:10.1093/schbul/sbw102 Advance Access publication July 22, 2016 SZDB: A Database for Schizophrenia Genetic Research Yong Wu1,2, Yong-Gang Yao1–4, and Xiong-Jian Luo*,1,2,4 1Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Kunming, China; 2Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, China; 3CAS Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, China 4YGY and XJL are co-corresponding authors who jointly directed this work. *To whom correspondence should be addressed; Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China; tel: +86-871-68125413, fax: +86-871-68125413, e-mail: [email protected] Schizophrenia (SZ) is a debilitating brain disorder with a Introduction complex genetic architecture. Genetic studies, especially Schizophrenia (SZ) is a severe mental disorder charac- recent genome-wide association studies (GWAS), have terized by abnormal perceptions, incoherent or illogi- identified multiple variants (loci) conferring risk to SZ. cal thoughts, and disorganized speech and behavior. It However, how to efficiently extract meaningful biological affects approximately 0.5%–1% of the world populations1 information from bulk genetic findings of SZ remains a and is one of the leading causes of disability worldwide.2–4 major challenge. There is a pressing
    [Show full text]
  • Lack of NMDA Receptor Subtype Selectivity for Hippocampal Long-Term Potentiation
    The Journal of Neuroscience, July 20, 2005 • 25(29):6907–6910 • 6907 Brief Communication Lack of NMDA Receptor Subtype Selectivity for Hippocampal Long-Term Potentiation Sven Berberich,1* Pradeep Punnakkal,1* Vidar Jensen,2 Verena Pawlak,1 Peter H. Seeburg,1 Øivind Hvalby,2 and Georg Ko¨hr1 1Department of Molecular Neurobiology, Max-Planck-Institute for Medical Research, D-69120 Heidelberg, Germany, and 2Molecular Neurobiology Research Group, Institute of Basic Medical Sciences, University of Oslo, N-0317 Oslo, Norway NMDA receptor (NMDAR) 2A (NR2A)- and NR2B-type NMDARs coexist in synapses of CA1 pyramidal cells. Recent studies using pharmacological blockade of NMDAR subtypes proposed that the NR2A type is responsible for inducing long-term potentiation (LTP), whereas the NR2B type induces long-term depression (LTD). This contrasts with the finding in genetically modified mice that NR2B-type NMDARs induce LTP when NR2A signaling is absent or impaired, although compensatory mechanisms might have contributed to this result. We therefore assessed the contribution of the two NMDAR subtypes to LTP in mouse hippocampal slices by different induction protocols and in the presence of NMDAR antagonists, including the NR2A-type blocker NVP-AAM077, for which an optimal concentra- tion for subtype selectivity was determined on recombinant and native NMDARs. Partial blockade of NMDA EPSCs by 40%, either by preferentially antagonizing NR2A- or NR2B-type NMDARs or by the nonselective antagonist D-AP-5, did not impair LTP, demonstrating that hippocampal LTP induction can be generated by either NMDAR subtype. Key words: NVP-AAM077; PEAQX; CP-101,606; recombinant; gene-targeted mouse; partial blockade; pairing Introduction Materials and Methods During postnatal development, the hippocampal signaling cas- Recombinant receptors.
    [Show full text]
  • Antidepresszánsok Nem Konvencionális Hatásai a Központi És Perifériás Idegrendszerben
    Antidepresszánsok nem konvencionális hatásai a központi és perifériás idegrendszerben Doktori értekezés Dr. Mayer Aliz Semmelweis Egyetem Szentágothai János Idegtudományi Doktori Iskola Témavezet ő: Dr. Kiss János, Ph.D. Hivatalos bírálók: Dr. Köles László egyetemi adjunktus, Ph.D. Dr. K őfalvi Attila tudományos f őmunkatárs, Ph.D. Szigorlati bizottság elnöke: Dr. Kecskeméti Valéria egyetemi tanár, az orvostudományok kandidátusa Szigorlati bizottság tagjai: Dr. Hársing László Gábor tudományos tanácsadó, az MTA doktora Dr. Tretter László, egyetemi docens, az orvostudományok kandidátusa Budapest 2009 TARTALOMJEGYZÉK 1. Rövidítések jegyzéke………………………………………………………………....3 2. Bevezetés…………………………………………………………………………...…4 3. Irodalmi háttér és el őzetes eredmények………………………………………........6 3.1. A monoamin teória és egyéb, alternatív depresszió-teóriák……………......……….6 3.2. Antidepresszánsok…………………………………………………………..………8 3.3. Antidepresszánsok hatása a központi idegrendszer nAChR-aira………………….11 3.4. A nAChR-ok és a monoamin transzporterek közös sajátságai ………………….....15 3.4.1. A központi idegrendszer nikotinos acetilkolin receptorai (nAChR)..............15 3.4.2. A monoamin transzporterek jellemz ői................….……………….……….18 3.5. Az ionotróp receptorok általános áttekintése …………………...............................21 4. Célkit űzések…………………………………………………………...……………36 5. Módszerek………………………………………………………………..…………38 5.1. In vitro szeletperfúziós technika……………………………………….....……......38 5.1.1. Tríciált noradrenalin [ 3H]NA felszabadulás mérése patkány hippokampusz
    [Show full text]
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders
    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
    [Show full text]
  • S308.3.008 Study
    Solvay Protocol No. S308.3.008 Clinical Report ID:SOLID 0000266607 20 JUL 2009 SYNOPSIS Name of Sponsor: Individual Study (For National Solvay Pharmaceuticals Table: Authority Name of Finished Product: Use only) Pardoprunox Name of Active Ingredient: Pardoprunox (SLV308) Study Title: An extension of the Vermeer study: An open-label SLV308 safety extension to study S308.3.003 in early PD patients Investigator(s): 56 Investigators. Study Center(s): 56 centers in 15 countries. Publication (Reference): Not applicable. Study Period: 26 JUN 2007 (first subject first visit) to 12 SEP 2008 (last subject last visit) Phase of Development: III Objectives: The primary objective of this study was to collect and evaluate long-term safety and tolerability data of pardoprunox (SLV308) treatment in early Parkinson’s disease (PD) patients. The secondary objectives were: • To collect descriptive efficacy data with respect to the motor functioning of PD patients and overall PD symptoms, including activities of daily living (ADL) and global clinical impression (CGI), after long-term treatment with pardoprunox in the dose range of 6-42 mg/day. • To investigate the effects of long-term pardoprunox treatment on health-related quality of life. • To collect and evaluate date on population-pharmacokinetics of pardoprunox. Methodology: This was a multicenter, six month open-label safety extension study for all subjects who were willing and eligible to continue treatment with pardoprunox after completion of the pivotal, double blind S308.3.003 trial (in the S308.3.003 study, approximately one third of subjects received pardoprunox, one third received pramipexole and one third received placebo). Prematurely withdrawn subjects from S308.3.003 study did not qualify for the extension study.
    [Show full text]